Transcript Overview - Medicines Transparency Alliance

Pricing: Observations
Nazeem Mohamed
Chairman, Uganda Pharmaceutical
Manufacturers Association (UPMA)
C.E.O. Kampala Pharmaceutical
Industries (1996) Ltd
08/04/2016
Medicines Transparency Alliance
Pricing: Information/Data Gathering





Robust methodologies and publications exist (WHO/HAI) on pricing
of medicines
Share data across countries on “public procurement” as means to
increase efficiency
Data must be shared across multi-sectors before policies are finalised –
Transparency is the key!!
Pricing/Affordability must go hand in hand
Convert prices into a Availability Index (no’s days wages to pay
for treatment)

A finding may have many causes!!

Information must be dynamic and communicated!!!
08/04/2016
Medicines Transparency Alliance
Pricing: Policy


Pricing is only one aspect of the “access” issue and there is NO
one answer!!
Effective policy will have to be a package of measures addressing
pricing, e.g.
–
Generic substitution
–
Price/margin controls
–
Procurement efficiency
–
Differential pricing
–
Support local manufacturing
–
Increase public sector availability

Need for a financing mechanism for the poor and even the near poor

Must measure the impact of policy and be prepared to adjust as
necessary
08/04/2016
Medicines Transparency Alliance
Pricing: Issues



Watch for unwanted negative effects
–
Price controls may impact on availability
–
Growth of cheaper sub standard products
Asymmetric information, i.e. Choice of medicine not made by the
end consumer!!
Consider the impact of “Chronic diseases” when developing policy
(priorities!)

Health system strengthening

Financing options
08/04/2016
Medicines Transparency Alliance
Pricing: MeTA Country Achievements
Country/MeTA Initiatives
Impact/Achievement
Pricing/Availability studies conducted in
different sectors (Ug,Zam)
-
Development of Price Observatory
(Peru)
- Price transparency
- Real time/on line data
Private Sector Mapping Survey
conducted (Zam)
Revealed pricing structures of selected
medicines in private sector
08/04/2016
Medicines Transparency Alliance
Stock outs highlighted
Differences in Public/Private sectors
Trends in availability highlighted
Recommendations made to justify
financing/health insurance
- Wider dissemination of studies to
other sectors
- Unaffordability highlighted
Pricing: MeTA Country Achievements
Country/MeTA Initiatives
Impact/Achievement
Pricing survey for essential medicines
to analyze prices in the decentralized
hospital procurement system and
private pharmacies. (KG)
-Expected to obtain pricing information
in the various sectors to address
improvement in policy
Review pharmacy and therapeutic
committees constitution and terms of
reference (JOR)
- include pharmacoeconomists and
cost-effectiveness within those
committees
Electronic essential drug price
monitoring system from manufacturers
to drug stores (PHL)
- Obtain actual prices along the
distribution chain. Reference for
procurement and index for reimbursement.
08/04/2016
Medicines Transparency Alliance
Thank you
Nazeem Mohamed
Email: [email protected]
08/04/2016
Medicines Transparency Alliance